Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorArduino Arduini
Life of this patent
Estimating the term…
Abstract
The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure.
Claims15
-4. (canceled)
A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a congestive heart failure subject comprising administering to a subject in need of the same an effective amount of a ligand of PPARα or a pharmaceutically acceptable salt thereof.
A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a congestive heart failure subject comprising administering to a subject in need of the same an effective amount of a ligand of PPARα, said ligand of PPARα being devoid of CPT1 inhibitory activity or a pharmaceutically acceptable salt thereof.
A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a subject being affected by heart failure unrelated to dyslipidaemic states, comprising administering to a subject in need of the same an effective amount of a ligand of PPARα, said ligand of PPARα being devoid of CPT1 inhibitory activity or a pharmaceutically acceptable salt thereof.
The method according to 13, wherein said ligand of PPARα is a fibrate or a pharmaceutically acceptable salt thereof.
A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a congestive heart failure subject comprising administering to a subject in need of the same an effective amount of clofibrate or a pharmaceutically acceptable salt thereof.
A method of normalizing end-diastolic pressure and increasing ventricular systolic pressure in a subject being affected by heart failure unrelated to dyslipidaemic states, comprising administering to a subject in need of the same an effective amount of clofibrate or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.